This open-label, single-arm trial (n=30) aimed to evaluate the effect of length of time on selective serotonin reuptake inhibitors (SSRIs) on the response to psilocybin-assisted therapy in individuals with mild-moderate Major Depressive Disorder (MDD).
All participants received a single dose of 25mg of psilocybin in a therapeutic setting. The study enrolled individuals with varying lengths of time on SSRI therapy, stratified into four groups based on the duration of SSRI treatment.
The primary outcome measure was assessed using the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16), with secondary outcomes including response and remission rates, depression severity measured by MADRS, and safety assessments. The study started on January 1, 2023, and was expected to be completed by March 14, 2023, but was ultimately withdrawn.
Trial Details
This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting. In order to investigate the effects of length of time on SSRI therapy, 30 participants with varying lengths of time on SSRI therapy will be enrolled, stratified into four groups: Group 1: ≤ 1 year Group 2: 1 to ≤ 5 years Group 3: 5 to ≤ 10 years Group 4: > 10 yearsNCT Number NCT05594667
Sponsors & Collaborators
CybinCybin is a for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021). It has raised $98 million US.